$WST
WEST PHARMACEUTICAL SERVICES INC Stock $wst

$wst Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000010577024000031 Filed on April 25, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$702.1M	$695.4M
YoY Change	-6.86%	-2.96%
Cost Of Revenue	$472.1M	$465.2M
YoY Change	2.1%	4.47%
Gross Profit	$230.0M	$230.2M
YoY Change	-21.07%	-15.15%
Gross Profit Margin	32.76%	33.1%
Selling, General & Admin	$83.00M	$86.70M
YoY Change	-6.11%	0.81%
% of Gross Profit	36.09%	37.66%
Research & Development	$17.50M	$17.60M
YoY Change	6.06%	2.92%
% of Gross Profit	7.61%	7.65%
Depreciation & Amortization	$38.90M	$35.60M
YoY Change	14.08%	15.96%
% of Gross Profit	16.91%	15.46%
Operating Expenses	$100.5M	$105.6M
YoY Change	-4.56%	2.42%
Operating Profit	$126.2M	$124.6M
YoY Change	-32.19%	-19.77%
Interest Expense	$2.500M	$3.400M
YoY Change	56.25%	54.55%
% of Operating Profit	1.98%	2.73%
Other Income/Expense, Net	$2.500M	$4.600M
YoY Change	257.14%	76.92%
Pretax Income	$128.7M	$127.4M
YoY Change	-30.39%	-19.32%
Income Tax	$21.90M	$16.40M
% Of Pretax Income	17.02%	12.87%
Net Earnings	$111.3M	$115.3M
YoY Change	-28.24%	-17.64%
Net Earnings / Revenue	15.85%	16.58%
Basic Earnings Per Share	$1.52	$1.57
Diluted Earnings Per Share	$1.51	$1.55
COMMON SHARES
Basic Shares Outstanding	72.84M shares	73.30M shares
Diluted Shares Outstanding	73.70M shares	74.30M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$446.2M	$601.8M
YoY Change	-43.97%	-32.1%
Cash & Equivalents	$446.2M	$601.8M
Short-Term Investments
Other Short-Term Assets	$138.2M	$137.2M
YoY Change	46.87%	51.6%
Inventory	$419.2M	$429.9M
Prepaid Expenses
Receivables	$479.4M	$524.0M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.483B	$1.693B
YoY Change	-20.87%	-12.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.494B	$1.545B
YoY Change	9.79%	27.17%
Goodwill	$107.3M	$107.6M
YoY Change	-0.65%	-0.19%
Intangibles	$12.90M	$13.90M
YoY Change	-23.21%	-21.91%
Long-Term Investments	$191.0M	$202.5M
YoY Change	-5.82%	0.8%
Other Assets	$50.10M	$40.00M
YoY Change	-53.31%	8.99%
Total Long-Term Assets	$2.006B	$1.909B
YoY Change	11.75%	6.89%
TOTAL ASSETS
Total Short-Term Assets	$1.483B	$1.693B
Total Long-Term Assets	$2.006B	$1.909B
Total Assets	$3.489B	$3.602B
YoY Change	-4.91%	-3.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$211.7M	$240.1M
YoY Change	-2.89%	2.69%
Accrued Expenses	$103.2M	$84.50M
YoY Change	1.57%	3.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$132.9M	$133.4M
YoY Change	5940.91%	5963.64%
Total Short-Term Liabilities	$633.7M	$648.4M
YoY Change	23.87%	21.22%
LONG-TERM LIABILITIES
Long-Term Debt	$72.90M	$72.80M
YoY Change	-64.54%	-64.68%
Other Long-Term Liabilities	$63.10M	$187.8M
YoY Change	-66.84%	236.56%
Total Long-Term Liabilities	$136.0M	$260.6M
YoY Change	-65.65%	-0.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$633.7M	$648.4M
Total Long-Term Liabilities	$136.0M	$260.6M
Total Liabilities	$912.6M	$921.7M
YoY Change	-1.12%	-2.71%
SHAREHOLDERS EQUITY
Retained Earnings	$3.721B	$3.624B
YoY Change	14.33%	16.4%
Common Stock	$18.80M	$18.80M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.577B	$2.681B
YoY Change
Total Liabilities & Shareholders Equity	$3.489B	$3.602B
YoY Change	-4.91%	-3.26%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$111.3M	$115.3M
YoY Change	-28.24%	-17.64%
Depreciation, Depletion And Amortization	$38.90M	$35.60M
YoY Change	14.08%	15.96%
Cash From Operating Activities	$165.0M	$118.2M
YoY Change	-2.48%	-14.41%
INVESTING ACTIVITIES
Capital Expenditures	$100.2M	$90.60M
YoY Change	32.89%	10.35%
Acquisitions
YoY Change
Other Investing Activities	-$1.000M
YoY Change	-85.07%
Cash From Investing Activities	-$101.2M	-$90.60M
YoY Change	23.26%	10.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-218.3M	-271.0M
YoY Change	23.47%	281.69%
NET CHANGE
Cash From Operating Activities	165.0M	118.2M
Cash From Investing Activities	-101.2M	-90.60M
Cash From Financing Activities	-218.3M	-271.0M
Net Change In Cash	-154.5M	-243.4M
YoY Change	72.24%	2942.5%
FREE CASH FLOW
Cash From Operating Activities	$165.0M	$118.2M
Capital Expenditures	$100.2M	$90.60M
Free Cash Flow	$64.80M	$27.60M
YoY Change	-30.92%	-50.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity File Number EntityFileNumber	1-8036
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	WEST PHARMACEUTICAL SERVICES, INC.
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000105770
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	WEST PHARMACEUTICAL SERVICES, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	PA
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	23-1210010
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	530 Herman O. West Drive
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Exton
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19341-1147
CY2024Q1	dei	City Area Code CityAreaCode	610
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	594-2900
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	72843157	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	695400000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	716600000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17600000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17100000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86700000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86000000.0	usd
CY2024Q1	wst	Other Income Expense OtherIncomeExpense	-3100000	usd
CY2023Q1	wst	Other Income Expense OtherIncomeExpense	-12900000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	122800000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	155300000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1600000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2200000	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	6200000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	4800000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	127400000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	157900000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16400000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23600000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4300000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5700000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	115300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	140000000.0	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.57
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.88
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.55
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.85
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73500000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74500000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74300000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75700000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	115300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	140000000.0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	1000000.0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	200000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-46300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	15300000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent	-0.0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent	200000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	200000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	500000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0.0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0.0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-100000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease Adjustments Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax	-700000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease Adjustments Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax	-100000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	-1900000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	-200000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-48500000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14600000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	66800000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	154600000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	601800000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	853900000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	524000000.0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	512000000.0	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	429900000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	434700000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	137200000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	135800000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1692900000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1936400000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2791300000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2738000000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1342700000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1324700000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1448600000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1413300000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	96800000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	99200000	usd
CY2024Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	202500000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	210000000.0	usd
CY2024Q1	us-gaap	Goodwill Goodwill	107600000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	108500000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	13900000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15100000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	21000000.0	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	25700000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19000000.0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21300000	usd
CY2024Q1	us-gaap	Assets Assets	3602300000	usd
CY2023Q4	us-gaap	Assets Assets	3829500000	usd
CY2024Q1	wst	Notes Payable And Other Debt Current NotesPayableAndOtherDebtCurrent	133400000	usd
CY2023Q4	wst	Notes Payable And Other Debt Current NotesPayableAndOtherDebtCurrent	134000000.0	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	240100000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	242400000	usd
CY2024Q1	wst	Accrued Salaries Wages And Benefits Current AccruedSalariesWagesAndBenefitsCurrent	66500000	usd
CY2023Q4	wst	Accrued Salaries Wages And Benefits Current AccruedSalariesWagesAndBenefitsCurrent	105900000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	16800000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	16600000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18000000.0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17700000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	173600000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	155200000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	648400000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	671800000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	72800000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	72800000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12700000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12700000	usd
CY2024Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	28900000	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	29600000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	82400000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	84500000	usd
CY2024Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	18600000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	18600000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	57900000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58500000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	921700000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	948500000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.25
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.25
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75300000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75300000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73500000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	18800000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	18800000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55200000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	120200000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3624100000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3523400000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-192300000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-143800000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2300000	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1800000	shares
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	825200000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	637600000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2680600000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2881000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3602300000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3829500000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	115300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	140000000.0	usd
CY2024Q1	us-gaap	Depreciation Depreciation	34700000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	30700000	usd
CY2024Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	900000	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	900000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5000000.0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8500000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9400000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	600000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1900000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3700000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	6500000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	34600000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	46800000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	118200000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	138100000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	90600000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82100000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-90600000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-82100000	usd
CY2024Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	600000	usd
CY2023Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	600000	usd
CY2024Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	14700000	usd
CY2023Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	14100000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14800000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13500000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	2000000.0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1800000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	267000000.0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	60100000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5400000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11500000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-100000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-271000000.0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-71000000.0	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-8700000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7000000.0	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-252100000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8000000.0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	853900000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	894300000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	601800000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	886300000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	21500000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	19900000	usd
CY2024Q1	wst	Contract With Customer Asset Increase Decrease ContractWithCustomerAssetIncreaseDecrease	-1600000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	53900000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	57900000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	-4000000.0	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	15500000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	115300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	140000000.0	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73500000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74500000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	800000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1200000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74300000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75700000	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	300000	shares
CY2023Q1	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	1000000000	shares
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	729679	shares
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	267000000	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	365.87
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	183360	shares
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	60100000	usd
CY2023Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	327.90
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	174000000.0	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	172300000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	81600000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	87300000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	174300000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	175100000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	429900000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	434700000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	5600000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	5900000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	500000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1300000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1900000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1700000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	8000000.0	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	6800000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	8900000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	5300000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4900000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4200000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	600000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y9M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0355
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0355
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	16000000.0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	20900000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19500000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16500000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11900000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11200000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10100000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9500000	usd
CY2024Q1	wst	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	41700000	usd
CY2023Q4	wst	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	42100000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	115700000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	118100000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15300000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15900000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	100400000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	102200000	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	195900000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	203200000	usd
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	6600000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	206400000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	207000000.0	usd
CY2024Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	200000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	200000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	206200000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	206800000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	133400000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	134000000.0	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	72800000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	72800000	usd
CY2024Q1	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	1800000	usd
CY2023Q1	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	-1200000	usd
CY2024Q1	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	9900000	usd
CY2024Q1	us-gaap	Foreign Currency Contract Asset Fair Value Disclosure ForeignCurrencyContractAssetFairValueDisclosure	500000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	33800000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3700000	usd
CY2024Q1	us-gaap	Other Deferred Compensation Arrangements Liability Classified Noncurrent OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent	10100000	usd
CY2024Q1	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	10300000	usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	24100000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.043
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.320
CY2023Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	10200000	usd
CY2023Q4	us-gaap	Foreign Currency Contract Asset Fair Value Disclosure ForeignCurrencyContractAssetFairValueDisclosure	5000000.0	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	34200000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3600000	usd
CY2023Q4	us-gaap	Other Deferred Compensation Arrangements Liability Classified Noncurrent OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent	10400000	usd
CY2023Q4	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	2200000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	16200000	usd
CY2024Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	70300000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	72800000	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	70800000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	72800000	usd
CY2024Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-49500000	usd
CY2024Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-1000000.0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-48500000	usd
CY2023Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	14200000	usd
CY2023Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-400000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14600000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2881000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	115300000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14400000	usd
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	267000000.0	usd
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.20
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	14600000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-48500000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2680600000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2684900000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	140000000.0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11000000.0	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	60100000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.19
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	14200000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14600000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2776200000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1357302	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	84140	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	350.18
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	134.81
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.003
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5000000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8500000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9400000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1200000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-900000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1000000.0	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	300000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	600000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1900000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-300000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-400000	usd
CY2024Q1	wst	Other Income Expense OtherIncomeExpense	-3100000	usd
CY2023Q1	wst	Other Income Expense OtherIncomeExpense	-12900000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9400000	usd
CY2023Q1	wst	Number Of Manufacturing Facilities Sold NumberOfManufacturingFacilitiesSold	1	facility
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16400000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23600000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.129
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.149
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-10900000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-11600000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q1	us-gaap	Revenues Revenues	695400000	usd
CY2023Q1	us-gaap	Revenues Revenues	716600000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	122800000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	155300000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4600000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2600000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	127400000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	157900000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9400000	usd
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0000105770-24-000031-index-headers.html	Edgar Link	pending
0000105770-24-000031-index.html	Edgar Link	pending
0000105770-24-000031.txt	Edgar Link	pending
0000105770-24-000031-xbrl.zip	Edgar Link	pending
ex101formof2024equityawa.htm	Edgar Link	pending
ex101formof2024equityawa001.jpg	Edgar Link	pending
ex101formof2024equityawa002.jpg	Edgar Link	pending
ex101formof2024equityawa003.jpg	Edgar Link	pending
ex101formof2024equityawa004.jpg	Edgar Link	pending
ex101formof2024equityawa005.jpg	Edgar Link	pending
ex101formof2024equityawa006.jpg	Edgar Link	pending
ex101formof2024equityawa007.jpg	Edgar Link	pending
ex101formof2024equityawa008.jpg	Edgar Link	pending
ex101formof2024equityawa009.jpg	Edgar Link	pending
ex101formof2024equityawa010.jpg	Edgar Link	pending
ex101formof2024equityawa011.jpg	Edgar Link	pending
ex101formof2024equityawa012.jpg	Edgar Link	pending
ex101formof2024equityawa013.jpg	Edgar Link	pending
ex101formof2024equityawa014.jpg	Edgar Link	pending
ex101formof2024equityawa015.jpg	Edgar Link	pending
ex101formof2024equityawa016.jpg	Edgar Link	pending
ex101formof2024equityawa017.jpg	Edgar Link	pending
ex101formof2024equityawa018.jpg	Edgar Link	pending
ex101formof2024equityawa019.jpg	Edgar Link	pending
ex101formof2024equityawa020.jpg	Edgar Link	pending
ex101formof2024equityawa021.jpg	Edgar Link	pending
ex101formof2024equityawa022.jpg	Edgar Link	pending
ex101formof2024equityawa023.jpg	Edgar Link	pending
ex101formof2024equityawa024.jpg	Edgar Link	pending
ex101formof2024equityawa025.jpg	Edgar Link	pending
ex101formof2024equityawa026.jpg	Edgar Link	pending
ex101formof2024equityawa027.jpg	Edgar Link	pending
ex101formof2024equityawa028.jpg	Edgar Link	pending
ex101formof2024equityawa029.jpg	Edgar Link	pending
ex101formof2024equityawa030.jpg	Edgar Link	pending
ex101formof2024equityawa031.jpg	Edgar Link	pending
ex101formof2024equityawa032.jpg	Edgar Link	pending
ex101formof2024equityawa033.jpg	Edgar Link	pending
ex101formof2024equityawa034.jpg	Edgar Link	pending
ex101formof2024equityawa035.jpg	Edgar Link	pending
ex101formof2024equityawa036.jpg	Edgar Link	pending
ex101formof2024equityawa037.jpg	Edgar Link	pending
ex101formof2024equityawa038.jpg	Edgar Link	pending
ex101formof2024equityawa039.jpg	Edgar Link	pending
ex101formof2024equityawa040.jpg	Edgar Link	pending
ex101formof2024equityawa041.jpg	Edgar Link	pending
ex101formof2024equityawa042.jpg	Edgar Link	pending
ex101formof2024equityawa043.jpg	Edgar Link	pending
ex101formof2024equityawa044.jpg	Edgar Link	pending
ex101formof2024equityawa045.jpg	Edgar Link	pending
ex101formof2024equityawa046.jpg	Edgar Link	pending
ex101formof2024equityawa047.jpg	Edgar Link	pending
ex101formof2024equityawa048.jpg	Edgar Link	pending
ex101formof2024equityawa049.jpg	Edgar Link	pending
ex101formof2024equityawa050.jpg	Edgar Link	pending
ex101formof2024equityawa051.jpg	Edgar Link	pending
ex101formof2024equityawa052.jpg	Edgar Link	pending
ex101formof2024equityawa053.jpg	Edgar Link	pending
ex101formof2024equityawa054.jpg	Edgar Link	pending
ex101formof2024equityawa055.jpg	Edgar Link	pending
ex101formof2024equityawa056.jpg	Edgar Link	pending
ex101formof2024equityawa057.jpg	Edgar Link	pending
ex101formof2024equityawa058.jpg	Edgar Link	pending
ex101formof2024equityawa059.jpg	Edgar Link	pending
ex101formof2024equityawa060.jpg	Edgar Link	pending
ex311q12024.htm	Edgar Link	pending
ex312q12024.htm	Edgar Link	pending
ex321q12024.htm	Edgar Link	pending
ex322q12024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wst-20240331.htm	Edgar Link	pending
wst-20240331.xsd	Edgar Link	pending
wst-20240331_def.xml	Edgar Link	unprocessable
wst-20240331_lab.xml	Edgar Link	unprocessable
wst-20240331_pre.xml	Edgar Link	unprocessable
wst-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
wst-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WST
WEST PHARMACEUTICAL SERVICES INC Stock $wst

2024 Q2 Form 10-Q Financial Statement

#000010577024000031 Filed on April 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WST WEST PHARMACEUTICAL SERVICES INC Stock $wst

2024 Q2 Form 10-Q Financial Statement

#000010577024000031 Filed on April 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WST
WEST PHARMACEUTICAL SERVICES INC Stock $wst